Clinical trials for Congenital generalized lipodystrophy
10 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGNCT06390306The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPPeking University People's Hospital · PI: Qian Jiang, MD
- ACTIVE NOT RECRUITINGNCT06092879Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in FranceNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGNCT05682924Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation BosutinibSamara State Medical University · PI: Sabina Cherenova
- RECRUITINGNCT05282108Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid LeukemiaHikma Pharmaceuticals LLC
- RECRUITINGPhase 2NCT05143840Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseAugusta University · PI: Jorge Cortes, MD
- RECRUITINGPHASE1, PHASE2NCT04925479Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 2NCT04626024Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationBaylor College of Medicine · PI: Martha P. Mims, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT03934372Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte Biosciences International Sàrl · PI: Mohammed-El-Amine Bensmaine, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03516279Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseECOG-ACRIN Cancer Research Group · PI: Amer Zeidan
- ACTIVE NOT RECRUITINGPhase 2NCT03654768Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaSWOG Cancer Research Network · PI: Kendra L Sweet